The DOI matches its Crossref record; 34 of the 37 references it cites were found in a registry or an index.
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Open accessAbstract
Background Metastatic DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer has a poor prognosis after treatment with conventional chemotherapy and exhibits high levels of tumour neoantigens, tumour-infiltrating lymphocytes, and checkpoint regulators. All of these features are associated with the response to PD-1 blockade in other tumour types. Therefore, we aimed to study nivolumab, a PD-1 immune checkpoint inhibitor, in patients with dMMR/MSI-H metastatic colorectal cancer.Methods In this ongoing, multicentre, open-label, phase 2 trial, we enrolled adults (aged ≥18 years) with histologically confirmed recurrent or metastatic colorectal cancer locally assessed as dMMR/MSI-H from 31 sites (academic centres and hospitals) in eight countries (Australia, Belgium, Canada, France, Ireland, Italy, Spain, and the USA). Eligible patients had progressed on or after, or been intolerant of, at least one previous line of treatment, including a fluoropyrimidine and oxaliplatin or irinotecan. Patients were given 3 mg/kg nivolumab every 2 weeks until disease progression, death, unacceptable toxic effects, or withdrawal from study. The primary endpoint was investigator-assessed objective response as per Response Evaluation Criteria in Solid Tumors (version 1.1). All patients who received at least one dose of study drug were included in all analyses. This trial is registered with ClinicalTrials.gov, number NCT02060188.Findings Of the 74 patients who were enrolled between March 12, 2014, and March 16, 2016, 40 (54%) had received three or more previous treatments. At a median follow-up of 12·0 months (IQR 8·6-18·0), 23 (31·1%, 95% CI 20·8-42·9) of 74 patients achieved an investigator-assessed objective response and 51 (69%, 57-79) patients had disease control for 12 weeks or longer. Median duration of response was not yet reached; all responders were alive, and eight had responses lasting 12 months or longer (Kaplan-Meier 12-month estimate 86%, 95% CI 62-95). The most common grade 3 or 4 drug-related adverse events were increased concentrations of lipase (six [8%]) and amylase (two [3%]). 23 (31%) patients died during the study; none of these deaths were deemed to be treatment related by the investigator.Interpretation Nivolumab provided durable responses and disease control in pre-treated patients with dMMR/MSI-H metastatic colorectal cancer, and could be a new treatment option for these patients.Funding Bristol-Myers Squibb.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn the citing paper
“Initial results demonstrated a 31% objective response rate and 69% demonstrated at least 12 weeks of stable disease [78].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [78]
In the citing paper
“The Checkmate-142 phase II study demonstrated the effectiveness of nivolumab in previously treated MSI-H mCRC patients [84].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [84]
In the citing paper
“Upon examining the subgroup analysis of this study, it was observed that patients without RAS or BRAF mutations achieved a 41% objective response rate with nivolumab. In comparison, the rate was 27% in RAS mutant patients.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [84]
In the citing paper
“Additionally, the efficacy of ICIs in phase II studies with dMMR/MSI and BRAFV600E tumors versus dMMR/MSI and BRAF wild type was similar [53,54,55,56].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“Recently, a combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, gained approval from the FDA for the treatment of previously treated MSI-H/dMMR mCRC [54,131].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“Nivolumab, an anti-PD1 monoclonal antibody (moAb), has been utilized since 1 August 2017, for MSI-H/dMMR mCRC, as evidenced by the CheckMate 142 study [54].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“The CHECKMATE 142 study reported that Nivolumab could provide a durable response in patients with dMMR/MSI-H metastatic colorectal cancer, proposing Nivolumab as a new treatment option in these patients [117].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [117]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Self-citationDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Cited by
Sorted by citations
Items 801–900 of 1,005
Dysfunctional tumor-infiltrating Vδ1 + T lymphocytes in microsatellite-stable colorectal cancer
Stary, V., Pandey, R. V., List, J., Kleißl, L., Deckert, F., Kabiljo, J., Laengle, J., Gerakopoulos, V., Oehler, R., Watzke, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51025-1 · Cited by 33
Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer
Fan, W., Su, F., Zhang, Y., Zhang, X., Du, Y., Gao, Y., Li, W., Hu, W., & Zhao, J. (2024) · Biomarker Research · doi:10.1186/s40364-024-00640-7 · Cited by 35
McAllister, M. J., Underwood, M. A., Leung, H. Y., & Edwards, J. (2018) · Translational research · doi:10.1016/j.trsl.2018.11.004 · Cited by 33
Update on systemic therapy for colorectal cancer: biologics take sides
Gbolahan, O. B., & O’Neil, B. H. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.01.12 · Cited by 33
Colorectal Cancer: An Update on Treatment Options and Future Perspectives.
Florescu-Ţenea, R. M., Kamal, A. M., Mitruț, P., Mitruţ, R., Ilie, D. S., Nicolaescu, A. C., & Mogoantă, L. (2019) · PubMed Central · doi:10.12865/chsj.45.02.02 · Cited by 35
Fiala, O., Šorejs, O., Šustr, J., Kučera, R., Topolčan, O., & Fínek, J. (2020) · Anticancer Research · doi:10.21873/anticanres.14063 · Cited by 34
Uraki, S., Ariyasu, H., Doi, A., Takeshima, K., Morita, S., Inaba, H., Furuta, H., Fukuhara, N., Inoshita, N., Nishioka, H., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082831 · Cited by 32
Gauci, M.-L., Baroudjian, B., Bédérède, U., Zeboulon, C., Delyon, J., Allayous, C., Madelaine, I., Eftekhari, P., Resche‐Rigon, M., Poté, N., et al. (2020) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2020.06.016 · Cited by 33
Hultin, S., Nahar, K. J., Menzies, A. M., Long, G. V., Fernando, S. L., Atkinson, V. G., Cebon, J. S., & Wong, M. G. (2020) · BMC Nephrology · doi:10.1186/s12882-020-02044-9 · Cited by 33
SFPQ Depletion Is Synthetically Lethal with BRAFV600E in Colorectal Cancer Cells
Klotz‐Noack, K., Klinger, B., Rivera, M., Bublitz, N., Uhlitz, F., Riemer, P., Lüthen, M., Sell, T., Kasack, K., Gastl, B., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108184 · Cited by 35
Molecular Characterization of Appendiceal Goblet Cell Carcinoid
Arai, H., Baca, Y., Battaglin, F., Kawanishi, N. K., Wang, J., Soni, S., Zhang, W., Millstein, J., Johnston, C., Goldberg, R. M., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0318 · Cited by 33
Self-citationUpdate on Strategies of Probiotics for the Prevention and Treatment of Colorectal Cancer
Tang, G., & Zhang, L. (2020) · Nutrition and Cancer · doi:10.1080/01635581.2020.1865420 · Cited by 32
Immunotherapy for the treatment of colorectal cancer
Lumish, M. A., & Cercek, A. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26357 · Cited by 34
Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer
Manz, S., Losa, M., Fritsch, R., & Scharl, M. M. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211002018 · Cited by 36
Luo, B., Zhang, Y., Zhang, C., Liu, X., & Shi, C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.001 · Cited by 33
Stein, M. K., Oluoha, O., Patel, K., & Vanderwalde, A. M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060518 · Cited by 33
Yang, C., Cao, F., Huang, S., & Zheng, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.717505 · Cited by 33
A synopsis of modern - day colorectal cancer: Where we stand
Ranasinghe, R., Mathai, M. L., & Zulli, A. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188699 · Cited by 35
Advances in immunotherapy for MMR proficient colorectal cancer
Lote, H., Starling, N., Pihlak, R., & Gerlinger, M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102480 · Cited by 36
The clinical and immune features of CD14 in colorectal cancer identified via large-scale analysis
Chen, D., & Wang, H. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106966 · Cited by 33
Morphological predictors for microsatellite instability in urothelial carcinoma
Sobrino-Reig, E., Meizoso, T., García, J., Varillas‐Delgado, D., & Martín, Y. B. (2021) · Diagnostic Pathology · doi:10.1186/s13000-021-01168-2 · Cited by 32
Wang, Q., Shen, X., Chen, G., & Du, J. (2023) · International Journal of Cancer · doi:10.1002/ijc.34464 · Cited by 32
Artificial intelligence-powered discovery of small molecules inhibiting CTLA-4 in cancer
Sobhani, N., Tardiel-Cyril, D. R., Chai, D., Generali, D., Li, J., Vazquez‐Perez, J., Lim, J. M., Morris, R. M., Bullock, Z. N., Davtyan, A., et al. (2024) · BJC Reports · doi:10.1038/s44276-023-00035-5 · Cited by 33
Hamid, M. A., Pammer, L. M., Lentner, T., Doleschal, B., Gruber, R., Kocher, F., Gasser, E., Jöbstl, A., Seeber, A., & Amann, A. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01583-w · Cited by 34
Zhang, J., Choi, H., Kim, Y., Park, J., Cho, S., Kim, E., Cho, A., Lee, J. Y., Choi, J., Low, C., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011346 · Cited by 34
Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential
Rico, G. T., & Price, T. J. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1444024 · Cited by 32
Ho, H., Chou, T., Yang, S.-H., Jiang, J., Chen, W.-S., Chao, Y., & Teng, H. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02942-y · Cited by 31
Efficacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancer
Волков, Н. М., Yanus, G. A., Ivantsov, A. O., Moiseenko, F. V., Matorina, O. G., Валерьевич, Б. И., Moiseyenko, V. M., & Имянитов, Е. Н. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00842-z · Cited by 32
Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
Krimphove, M. J., Tully, K. H., Friedlander, D. F., Marchese, M., Ravi, P. K., Lipsitz, S. R., Kilbridge, K. L., Kibel, A. S., Kluth, L. A., Ott, P. A., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0782-y · Cited by 32
Improvements in Clinical Outcomes for BRAFV600E-Mutant Metastatic Colorectal Cancer
Morris, V. K., & Bekaii‐Saab, T. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3809 · Cited by 30
Genomics-guided pre-clinical development of cancer therapies
Francies, H. E., McDermott, U., & Garnett, M. J. (2020) · Nature Cancer · doi:10.1038/s43018-020-0067-x · Cited by 32
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer
Duchemann, B., Remón, J., Naigeon, M., Cassard, L., Jouniaux, J.-M., Boselli, L., Grivel, J., Auclin, É., Desnoyer, A., Besse, B., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-839 · Cited by 33
Sanaei, M., Pourbagheri‐Sigaroodi, A., Kaveh, V., Sheikholeslami, S. A., Salari, S., & Bashash, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103160 · Cited by 34
Chen, H., Jiang, T., Lin, F.-Y., Guan, H., Zheng, J., Liu, Q., Du, B., Huang, Y., & Lin, X. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107929 · Cited by 32
Antoniotti, C., Korn, W. M., Marmorino, F., Rossini, D., Lonardi, S., Masi, G., Randon, G., Conca, V., Boccaccino, A., Tomasello, G., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.06.037 · Cited by 33
Self-citationWen, X., Xu, Z., Jin, Y., Xia, P., Ma, J., Qian, W., Lin, J., & Qian, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.717527 · Cited by 33
Kothari, A. N., White, M. G., Peacock, O., Kaur, H., Palmquist, S. M., You, N., Taggart, M. W., Salem, U. I., Overman, M. J., Kopetz, S., et al. (2022) · British journal of surgery · doi:10.1093/bjs/znac050 · Cited by 33
Self-citationDisrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity
Anderson, T. S., McCormick, A. L., Piersall, S. L., Okpalanwaka, I. F., & Lowe, D. B. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.009 · Cited by 32
Shen, C., Tannenbaum, D., Horn, R. G., Rogers, J. E., Eng, C., Zhou, S., Johnson, B., Kopetz, S., Morris, V. K., Overman, M. J., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.13588 · Cited by 32
Self-citationJung, M., Lee, J. A., Yoo, S., Bae, J. M., Kang, G. H., & Kim, J. H. (2022) · Modern Pathology · doi:10.1038/s41379-022-01137-0 · Cited by 30
Qin, S., Li, J., Zhong, H., Jin, C., Chen, L., Yuan, X., Fan, Q., Chen, K., Cao, P., Xiao, J., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02001-3 · Cited by 33
Chang, Y., Lin, W.-Y., Chang, Y.-C., Huang, C.-H., Tzeng, H.-E., Abdul-Lattif, E., Wang, T.-H., Tseng, T.-H., Kang, Y., & Chi, K. (2022) · Cancers · doi:10.3390/cancers15010284 · Cited by 31
Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date
Nikoo, M., Rabiee, F., Mohebbi, H., Eghbalifard, N., Rajabi, H., Yazdani, Y., Sakhaei, D., Khosravifarsani, M., & Akhavan‐Sigari, R. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109881 · Cited by 33
Greco, L., Rubbino, F., Buono, A. D., & Laghi, L. (2023) · Genes · doi:10.3390/genes14061169 · Cited by 35
de la Fouchardière, C., Cohen, R., Malka, D., Guimbaud, R., Bourien, H., Lièvre, A., Cacheux, W., Artru, P., François, É., Gilabert, M., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0914 · Cited by 32
Cofano, F., Monticelli, M., Ajello, M., Zenga, F., Marengo, N., Perna, G. D., Altieri, R., Cassoni, P., Bertero, L., Melcarne, A., et al. (2019) · Cancer Control · doi:10.1177/1073274819870549 · Cited by 32
Kim, S. Y., & Kim, T. W. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000634 · Cited by 33
Asano, T., Ohishi, T., Takei, J., Nakamura, T., Nanamiya, R., Hosono, H., Tanaka, T., Sano, M., Harada, H., Kawada, M., et al. (2021) · Oncology Reports · doi:10.3892/or.2021.8124 · Cited by 30
Krieg, C., Weber, L. M., Fosso, B., Marzano, M., Hardiman, G., Olcina, M. M., Domingo, E., Aidy, S. E., Mallah, K., Robinson, M. D., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004717 · Cited by 29
Saberzadeh-Ardestani, B., Jones, J. C., McWilliams, R. R., Tougeron, D., Halfdanarson, T. R., Guimbaud, R., Hubbard, J. M., Flecchia, C., Shi, Q., Alouani, E. L., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113433 · Cited by 32
Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions
Younis, A., & Gribben, J. G. (2024) · Immuno · doi:10.3390/immuno4030013 · Cited by 34
Deficient Mismatch Repair and Microsatellite Instability in Solid Tumors
Awosika, J. A., Gulley, J. L., & Pastor, D. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094394 · Cited by 38
The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine
Riley, J. M., Cross, A. W., Paulos, C. M., Rubinstein, M. P., Wrangle, J. M., & Camp, E. R. (2018) · Cancer · doi:10.1002/cncr.31214 · Cited by 31
BRAF Mutation and Its Importance in Colorectal Cancer
Luu, L., & Price, T. J. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82571 · Cited by 31
Chen, M., Chang, S., Lin, P.-C., Yang, S.-H., Lin, C., Lan, Y., Lin, H., Lin, C., Lai, J., Liang, W.-Y., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0171 · Cited by 31
Shimizu, Y., Yoshikawa, T., Kojima, T., Shoda, K., Nosaka, K., Mizuno, S., Wada, S., Fujimoto, Y., Sasada, T., Kohashi, K., et al. (2019) · Cancer Science · doi:10.1111/cas.14165 · Cited by 31
Functional Diversity of Myeloid-Derived Suppressor Cells: The Multitasking Hydra of Cancer
Jayakumar, A., & Bothwell, A. L. M. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900500 · Cited by 30
Upregulation of TIGIT and PD-1 in Colorectal Cancer with Mismatch-repair Deficiency
Zhou, X., Ding, X., Li, H., Yang, C. K., Ma, Z., Xu, G., Yang, S., Zhang, D., Xie, X., Lei, X., et al. (2020) · Immunological Investigations · doi:10.1080/08820139.2020.1758130 · Cited by 32
Diabetes mellitus induced by immune checkpoint inhibitors
Zheng, Z., Liu, Y., Yang, J., Tan, C., Zhou, L., Wang, X., Li, X., Zhang, S., Chen, Y., & Liu, X. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3366 · Cited by 32
Kim, H., Hong, J. Y., Lee, J., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Kang, W. K., Kim, K., & Kim, S. T. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921992992 · Cited by 34
Emerging Trends for Radio-Immunotherapy in Rectal Cancer
Corrò, C., Dutoit, V., & Koessler, T. (2021) · Cancers · doi:10.3390/cancers13061374 · Cited by 33
Fucà, G., Corti, F., Ambrosini, M., Intini, R., Salati, M., Fenocchio, E., Manca, P., Manai, C., Daniel, F., Raimondi, A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002501 · Cited by 31
Self-citationShek, D., Akhuba, L. G., Carlino, M. S., Nagrial, A. M., Moujaber, T., Read, S. A., Gao, B., & Ahlenstiel, G. (2021) · Cancers · doi:10.3390/cancers13174345 · Cited by 32
Han, K., Tang, J., Liao, L., Jiang, W., Sui, Q., Xiao, B., Li, W.-R., Hong, Z., Li, Y., Kong, L.-H., et al. (2022) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000002466 · Cited by 31
Neoadjuvant immunotherapy in gastrointestinal cancers – The new standard of care?
Petričević, B., Kabiljo, J., Zirnbauer, R., Walczak, H., Laengle, J., & Bergmann, M. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.015 · Cited by 32
Mazzoli, G., Cohen, R., Lonardi, S., Corti, F., Élez, E., Fakih, M., Jayachandran, P., Colle, R., Shah, A. T., Salati, M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.044 · Cited by 32
Self-citationMishima, S., Taniguchi, H., Akagi, K., Baba, E., Fujiwara, Y., Hirasawa, A., Ikeda, M., Maeda, O., Muro, K., Nishihara, H., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01498-8 · Cited by 30
The Impact of Cancer Stem Cells in Colorectal Cancer
Radu, P., Zurzu, M., Tigora, A., Paic, V., Bratucu, M., Garofil, D., Surlin, V., Munteanu, A. C., Coman, I. S., Popa, F., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084140 · Cited by 30
CD166-specific CAR-T cells potently target colorectal cancer cells
He, S., Li, S., Guo, J., Zeng, X., Liang, D., Zhu, Y., Li, Y., Yang, D., & Zhao, X. (2023) · Translational Oncology · doi:10.1016/j.tranon.2022.101575 · Cited by 30
Alouani, E. L., Mercier, M., Flecchia, C., Auclin, É., Hollebecque, A., Mazard, T., Turpin, A., Pernot, S., Cohen, R., Dutherage, M., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101574 · Cited by 29
Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy
Saini, K. S., Somara, S., Ko, H. C., Thatai, P., Quintana, A., Wallen, Z. D., Green, M. F., Mehrotra, R., McGuigan, S., Pang, L., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1473706 · Cited by 31
p53 in colorectal cancer: from a master player to a privileged therapy target
Yan, S., Zhan, F., He, Y., Zhu, Y., & Ma, Z. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06566-4 · Cited by 33
Immunotherapy in colorectal cancer
Agarwal, P., Le, D. T., & Boland, P. M. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.03.002 · Cited by 31
Progress of immune checkpoint therapy in the clinic (Review)
Fan, Y., Zhang, C., Jin, S., Gao, Z., Cao, J., Wang, A., Li, D., Wang, Q., Sun, X., & Bai, D. (2018) · Oncology Reports · doi:10.3892/or.2018.6819 · Cited by 30
Jansen, C. S., Prokhnevska, N., & Kissick, H. T. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.10.011 · Cited by 29
Syndrome de Lynch : quoi de neuf ?
Pellat, A., Netter, J., Perkins, G., Cohen, R., Coulet, F., Parc, Y. R., Svrcek, M., Duval, A., & André, T. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.10.009 · Cited by 30
Self-citationHenry, J. T., & Johnson, B. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.08.08 · Cited by 29
Forster, S., & Radpour, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.569017 · Cited by 31
Wang, Q., Qu, C., Gao, Y., Ding, P., Yun, J., Xie, D., & Cai, M. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00193-z · Cited by 30
Autophagy controls programmed death‑ligand 1 expression on cancer cells (Review)
Gao, L., & Chen, Y. (2021) · Biomedical Reports · doi:10.3892/br.2021.1460 · Cited by 32
Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model
Abdolahi, S., Ghazvinian, Z., Muhammadnejad, S., Ahmadvand, M., Aghdaei, H. A., Ebrahimi‐Barough, S., Ai, J., Zali, M. R., Verdi, J., & Baghaei, K. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.733075 · Cited by 30
Witte, H. M., Künstner, A., Hertel, N., Bernd, H., Bernard, V., Stölting, S., Merz, H., von Bubnoff, N. C. C., Busch, H. S., Feller, A. C., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005486 · Cited by 30
Yang, K., Han, L., Wu, S., Qu, X., Li, Q., Zhao, C., Zhou, J., Jin, X. S., Wang, Y., Dong, Y., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03083-3 · Cited by 30
Jan, Y., Tan, K. T., Chen, S., Yip, T. T. C., Lu, C., & Lam, A. K.-Y. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01913-4 · Cited by 29
van den Bulk, J., van der Ploeg, M., Ijsselsteijn, M. E., Ruano, D., van der Breggen, R., Duhen, R., Peeters, K. C. M. J., Sarasqueta, A. F., Verdegaal, E. M. E., van der Burg, S. H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005887 · Cited by 32
Xu, Y., Nowsheen, S., & Deng, M. (2023) · Cancers · doi:10.3390/cancers15051619 · Cited by 31
Zhao, L., Yang, Y., Li, W., Li, T., & Gao, Q. (2018) · Immunotherapy · doi:10.2217/imt-2018-0025 · Cited by 30
Pembrolizumab for the treatment of colorectal cancer
Coupez, D., Hulo, P., Touchefeu, Y., Bossard, C., & Bennouna, J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1718095 · Cited by 32
Gyawali, B., D’Andrea, E., Franklin, J. M., & Kesselheim, A. S. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7345 · Cited by 33
Ben, S., Zhu, Q., Chen, S., Li, S., Du, M., Xin, J., Chu, H., Zhang, Z., & Wang, M. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03040-0 · Cited by 29
Aiyer, K. T. S., Doeleman, T., Ryan, N. A. J., Nielsen, M., Crosbie, E. J., Smit, V. T. H. B. M., Morreau, H. M., Goeman, J. J., & Bosse, T. (2022) · Modern Pathology · doi:10.1038/s41379-022-01149-w · Cited by 29
Onciul, R., Brehar, F.-M., Toader, C., Covache-Busuioc, R.-A., Glavan, L.-A., Bratu, B.-G., Costin, H. P., Dumitrascu, D.-I., Șerban, M., & Ciurea, A. V. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46030153 · Cited by 30
Therapeutic targeting of mismatch repair-deficient cancers
Johannet, P. M., Rousseau, B., Aghajanian, C. A., Foote, M. B., & Diaz, L. A. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01054-6 · Cited by 35
Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Wang, S., Zhou, D., Xu, Z., Song, J., Qian, X., Lv, X., & Luan, J. (2019) · Current Drug Targets · doi:10.2174/1389450120666190402145325 · Cited by 29
Damilakis, E., Mavroudis, D., Sfakianaki, M., & Souglakos, J. (2020) · Cancers · doi:10.3390/cancers12040889 · Cited by 30
Moretto, R., Corallo, S., Belfiore, A., Rossini, D., Boccaccino, A., Lonardi, S., Centonze, G., Morano, F., Germani, M. M., Loupakis, F., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.04.045 · Cited by 29
Self-citationThe Landscape of Tumor-Specific Antigens in Colorectal Cancer
Bakarurraini, N. A. A. R., Mutalib, N. A., Jamal, R., & Abu, N. (2020) · Vaccines · doi:10.3390/vaccines8030371 · Cited by 30
Al-Badran, S. S. F., Grant, L., Campo, M. V., Inthagard, J., Pennel, K. A. F., Quinn, J. A., Konanahalli, P., Hayman, L., Horgan, P. G., McMillan, D., et al. (2020) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.193 · Cited by 29
Novel Perspectives in Pseudomyxoma Peritonei Treatment
Sommariva, A., Tonello, M., Rigotto, G., Lazzari, N., Pilati, P., & Calabrò, M. L. (2021) · Cancers · doi:10.3390/cancers13235965 · Cited by 29
Gorzo, A., Galoș, D., Volovăț, S. R., Lungulescu, C. V., Burz, C. C., & Sur, D. G. (2022) · Life · doi:10.3390/life12020229 · Cited by 30
Metadata
- Authors
- Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., Goldberg, M. V., Cao, Z. A., Ledeine, J.-M., Maglinte, G. A., Kopetz, S., & André, T.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Cancer Trials Ireland (IE)
- Allina Health (US)
- Istituto Oncologico Veneto (IT)
- USC Norris Comprehensive Cancer Center (US)
- Duke Medical Center (US)
- The Royal Melbourne Hospital (AU)
- Bristol-Myers Squibb (United States) (US)
- Bristol-Myers Squibb (Belgium) (BE)
- Sorbonne Université (FR)
- Corresponding author
- Overman, Michael J
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 18
- Issue
- 9
- Pages
- 1182-1191
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC6207072
- OpenAlex
- W2739132742
- Cited by
- 2,836
- References
- 37
- Citations by year
- 2026: 185 · 2025: 242 · 2024: 302 · 2023: 382 · 2022: 377 · 2021: 438 · 2020: 361 · 2019: 288 · 2018: 223 · 2017: 31
- FWCI
- 108.88
- Type
- journal article
- Language
- en
- Update notices
- erratum (2017-09-01)
- Open access
- green
- europepmc.org
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- National Institutes of Health (UL1TR000371)
- National Cancer Institute (P30CA016672)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- nivolumab, metastatic colorectal cancer, mismatch repair deficiency, microsatellite instability-high, PD-1 inhibitors, immune checkpoint blockade, objective response rate, disease control rate, progression-free survival, overall survival, treatment toxicity, first-line therapy, second-line therapy, third-line therapy, neoantigens, tumor-infiltrating lymphocytes
- MeSH terms
- Nivolumab, Adult, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Female, Humans, Male, Middle Aged, Colorectal Neoplasms, Treatment Outcome, Disease-Free Survival, Microsatellite Instability, DNA Mismatch Repair, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
